郑州微飒生物科技有限责任公司 咨询热线：0371-88821766
行业动态

行业动态

追踪行业前沿，洞察产业趋势

药效评价Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

期刊：Journal of medicinal chemistry发表年份：2018作者：Mariama Jaiteh; Alexey Zeifman; Marcus Saarinen; Per Svenningsson; Jose Bréa; Maria Isabel Loza; Jens Carlsson
阅读更多 →

药效评价Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors.

期刊：Naunyn-Schmiedeberg's archives of pharmacology发表年份：2018作者：Matthias Irmen; Janine Holze; Theresa Bödefeld; Christian Tränkle
阅读更多 →

药效评价Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

期刊：The Journal of clinical investigation发表年份：2018作者：Peter Ulrichts; Antonio Guglietta; Torsten Dreier; Tonke van Bragt; Valérie Hanssens; Erik Hofman; Bernhardt Vankerckhoven; Peter Verheesen; Nicolas Ongenae; Valentina Lykhopiy; F Javier Enriquez; JunHaeng Cho; Raimund J Ober; E Sally Ward; Hans de H
阅读更多 →

药效评价Discovery of artificial VIPR2-antagonist peptides possessing receptor- and ligand-selectivity.

期刊：Biochemical and biophysical research communications发表年份：2018作者：Kotaro Sakamoto; Ryokichi Koyama; Yusuke Kamada; Masanori Miwa; Akiyoshi Tani
阅读更多 →